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Abstract
Purpose Women with polycystic ovary syndrome (PCOS) exhibit many metabolic abnormalities that are associated with an in-
creased cardiovascular disease risk. Exercisemay promote improvements in lipid profile and insulin sensitivity inwomenwith PCOS.
There is however, a knowledge gap on the optimal dose of exercise, regarding duration, intensity, type, and frequency of exercise. The
aim of this systematic review andmeta-analysis was to define effective types of exercise to improve cardiometabolic profile in PCOS.
Methods We included randomised controlled trials (RCT), quasi-RCT, and controlled clinical trials focusing on reproductive-
agedwomen diagnosed with PCOS. Eligible interventions included those with at least two weeks of supervised exercise sessions.
Primary outcomes were blood lipids, blood glucose, blood pressure, measures of abdominal adiposity, and inflammation
markers. Secondary outcomes were total and free testosterone, sex hormone binding globulin, and measures of insulin resistance.
Nine electronic databases were searched from inception to present for English language publications. The Cochrane Risk
Assessment tool was used to assess bias in the included studies. Outcomes were quantitatively synthesised and a meta- analysis
was performed. Pooled effect estimates and 95% confidence intervals were presented.
Results This systematic review identified three trials, including 231 participants with PCOS, that examined the effect of struc-
tured, supervised exercise on cardiometabolic outcomes. Analysis of pooled data indicated statistical favourable effects of
exercise on total cholesterol, fasting glucose, waist circumference and waist-to-hip ratio, systolic blood pressure, C-reactive
protein, total testosterone, and sex hormone binding globulin using post-intervention scores.
Conclusions Moderate aerobic exercise interventions ≥3 months in duration, with a frequency of 3/week for at least 30-min, may
have favourable effects on various cardiometabolic risk factors in women with PCOS. However, results should be interpreted
with caution.Many of the outcomes were based on studies with serious methodological limitations, and only one “gold-standard”
RCTwas identified.
PROSPERO ID: CRD42018086117.
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Background
Polycystic ovary syndrome (PCOS) is a common complex
hormonal and metabolic condition [1]. The now internation-
ally accepted Rotterdam Criteria, derived by the European
Society of Human Reproduction and Embryology (ESHRE)
and the American Society for Reproductive Medicine
(ASRM), requires that women present with at least two of
the three signs/symptoms (clinical or biochemical
hyperandrogenism, anovulation or oligomenorrhea, and poly-
cystic ovaries) to receive a diagnosis, in the absence of other
pathologies that can promote these symptoms [2].
The metabolic complications associated with an increased
cardiovascular disease (CVD) risk in PCOS, independent of
obesity [3], include insulin resistance, impaired glucose toler-
ance (IGT), dyslipidemia, type 2 diabetes (T2D), hyperten-
sion, subclinical atherosclerosis, and a two to four-fold higher
prevalence of metabolic syndrome compared to body mass
index (BMI)-matched women [4–7]. Dyslipidemia,
characterised by high triglyceride (TG) and low high-density
lipoprotein (HDL) concentrations, is prevalent in up to 70% of
women with PCOS [5].
Inflammatory markers that are implicated in the mediation
of CVD may be elevated in women with PCOS [8]. These
markers range from high-sensitivity C-reactive protein [9, 10]
to increased white cell count, neutrophil/lymphocyte ratio,
tumour-necrosis factor-alpha (TNF-a) and interleukin-6 (IL-
6) [10–13]. Moreover, a 2012 review indicates that various
studies have reported that carotid intima-media thickness
(cIMT), a marker of subclinical atherosclerosis, is higher in
women with PCOS in comparison to controls [14].
Hyperandrogenism is associated with hyperinsulinemic
states because insulin has the capacity to act as a co-gonado-
trophin, thus stimulating ovarian androgen production [15].
The increased circulating androgens may then contribute
to inflammation by promoting adipocyte hypertrophy
and stimulating mononuclear cells to release TNF-a
and IL-6 [16]. In addition, hyperandrogenism may then
promote abdominal fat accumulation and further exacer-
bate insulin resistance. Phenotypes that present with
hyperandrogenism may therefore have a worse metabol-
ic profile despite comparable distributions of body weight
[17, 18].
Lifestyle interventions and modifications are widely con-
sidered to be a cornerstone of PCOS treatment for cardiomet-
abolic symptoms [19, 20]. Exercise interventions in PCOS
have promoted improvements in lipid profile, ovulation, and
insulin sensitivity by up to 30% in women with PCOS, inde-
pendent of weight loss, within 12 weeks [21]. This indicates
that the increased CVD risk factors associated with PCOS are
not solely attributed to obesity, and lean women with PCOS
can still benefit from exercise to improve their cardiometabol-
ic profile.
There currently lacks guidance on which exercise interven-
tions are effective for differing phenotypes, regarding dura-
tion, type of exercise and frequency of exercise sessions.
Subsequently, the objective of this systematic review and
meta-analysis is to define regimes of exercise interventions,
which could improve the cardiometabolic profile across a
range of phenotypes of PCOS.
Methods
The review is reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines and was pre-registered in the
International Prospective Register of Systematic Reviews
(PROSPERO): CRD42018086117. The full protocol is de-
scribed elsewhere [22].
Eligibility criteria
Randomised-controlled Trials (RCT), quasi-RCT, and clinical
trials were screened according to Population, Intervention,
Comparison and Outcome (PICO) criteria: participants were
reproductive aged women diagnosed with PCOS according to
Rotterdam Criteria 2003 [23], National Institute of Health
(NIH) 1990 criteria [24], or Androgen Excess and Polycystic
Ovary Syndrome (AE-PCOS) Society 2006 criteria [25].
They were excluded if they were undergoing fertility treat-
ment, taking metformin or OCP, undertaking regular exercise
training, or had a diagnosis of any pathology that may be
promoting PCOS symptoms.
The intervention could encompass aerobic exercise
training, anaerobic exercise training, resistance training,
or combinations, of at least two weeks in duration of
structured, supervised sessions only. Sessions could be
conducted in any setting, as groups or individuals.
Crossover trials and interventions that were combined
(such as a lifestyle intervention including both exercise
and diet management) were excluded. Studies had to
include a control group of women with PCOS undertaking
no interventions.
Outcomes must have been measured pre-intervention and
immediately post-intervention. Primary outcomes identified
included low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), total cholesterol
(TC), TC:HDL ratio, TG, oxidised LDL, cIMT, fasting blood
glucose, HbA1c, blood pressure, waist circumference (WC),
waist-to-hip ratio (WHR), abdominal adiposity and any in-
flammation markers.
Secondary outcomes included total testosterone, free tes-
tosterone, sex hormone binding globulin (SHBG), fasting in-
sulin, and homeostatic model assessment for insulin resistance
(HOMA-IR).
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Searches
The electronic databases as follows were searched from incep-
tion to present: CINAHLComplete (EBSCO), CochraneCentral
Register of Controlled Trials (CENTRAL) (Wiley), MEDLINE
(EBSCO), Scopus (Elsevier), SPORTDiscus (EBSCO), PEDro
(The University of Sydney), PubMed (US National Library of
Medicine), ClinicalTrials.gov and UK Clinical Trials Gateway.
Only English language publications were sought. Search terms
used were PCOS or polycystic ovary syndrome and terms
relating to exercise or physical activity interventions. These
were adapted for use with all databases; the PubMed search
strategy can be found in Online Resource 1.
Data collection and analysis
Study selection
Results from the database searches were imported into
RefWorks (ProQuest) and duplicate records were removed.
Screening was undertaken in Microsoft Excel (version 16.0).
At title and abstract screening phase one reviewer (AW)
screened all studies, with a second reviewer screening all in
duplicate (MK and DRB).
The full-text of the remaining studies were screened byAW
to determine their eligibility for inclusion in the review, with
each study checked independently by a second reviewer (MK
or DRB). Reasons for exclusion were recorded. Throughout
all stages, disagreement between two reviewers was resolved
by discussion and input from a third reviewer until a consen-
sus was reached.
Data extraction
An a priori data extraction form was created in Microsoft
Excel (version 16.0). AW extracted all data using the form,
with MK and DRB each independently checking all data for
consistency. Extracted data included bibliographic informa-
tion, study characteristics, participant characteristics, interven-
tion and comparison data including adherence and attrition
rates, and outcome data including any relevant parameters
named in the primary and secondary outcomes. In the case
of any missing or unclear data, two attempts were made to
contact the corresponding author by email. If no response was
received, the missing data was not included in the meta-
analysis.
Risk of bias in individual studies & heterogeneity
The Cochrane Risk of Bias Assessment tool [26] was used to
assess quality at the study level as high, low, or unclear risk of
bias. The tool evaluates studies based on seven criteria: 1)
Fig. 1 PRISMA flow-chart
From: Moher D, Liberati A,
Tetzlaff J, Altman DG, The
PRISMA Group (2009).
Preferred Reporting Items for
Systematic Reviews and
Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7):
e1000097. https://doi.org/10.
1371/journal.pmed100009
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randomisation generation, 2) allocation concealment, 3)
blinding of outcome assessors, 4) blinding patients/
study personnel, 5) incomplete outcome data (that is,
lost to follow-up), 6) selective outcome reporting, and 7) other
risks of bias.
Heterogeneity of results was assessed using the I2 statistic.
This statistic was chosen for its simplicity and applicability to
meta-analyses regardless of the number of studies involved as
described in the literature [27]. It describes the variabil-
ity, presented as a percentage, in effect estimates that is
due to heterogeneity rather than sampling error and is
interpreted as follows: 0–40%: might not be important,
30–60%: may represent moderate heterogeneity, 50–
90%: may represent substantial heterogeneity, and 75–
100%: considerable heterogeneity A result of over 50%
was considered significant heterogeneity [28]. Sensitivity
analyses were performed as appropriate by removing studies
with small sample sizes (<30) or those with a high risk of
selection bias.
Data synthesis
Outcomes measured and presented pre and post intervention
were quantitatively synthesised and analysed using RevMan 5
[29]. The I2 statistic, as well as considering clinical and meth-
odological heterogeneity, was used to determine whether
random-effects or fixed-effects meta-analysis was used.
Forest plots were generated where a P value of <0.05 was
considered statistically significant. Each outcome for each
study was recorded with mean and standard deviation (SD)
of each group, effect size (difference between means), 95%
confidence intervals (CI), and study weighting. Pooled mean
difference, 95% CI, P-values and I2 statistic were also record-
ed for each outcome.
Confidence in findings
The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) tool was used to grade the quality of
Fig. 2 Risk of bias graph.
Review authors’ judgements
about each risk of bias item
presented as percentages across
all included studies
Fig. 3 Risk of bias summary.
Review authors’ judgements
about each risk of bias item for
each included study
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the evidence and the strength of each finding [30]. GRADE
uses a scoring system (very low, low, moderate, high) to grade
each finding in several areas including limitations, consistency,
directness, and publication bias. The use of a consistent and
transparent approach to evaluating recommendations increases
the facilitation of critical appraisal and improves communica-
tion of these judgments [30].
Results
Results of the search
The initial search of databases identified a combined total of
2,334 records. Once duplicates were removed, 2,163 records
remained for title and abstract screening. Records were ex-
cluded (n = 2,136) because the title and abstract screening
revealed that the articles did not meet the inclusion criteria.
Twenty-seven articles were selected for full-text eligibility
screening. Twenty-four were excluded for the reasons identi-
fied in Fig. 1.
Study design and data handling
Three studies were included in the meta-analysis. One was an
exercise only RCT [31] and two were exercise only non-
randomised clinical trials [32, 33] All compared an exercise
intervention to a control group or standard care.
Two studies presented data as mean and SD [31, 32], and
one presented data as mean and 95% CI [33]. Data from the
latter study were converted into mean and SD. Data were
converted into the most common unit used for each variable
if there were discrepancies.
Sensitivity analysis was performed either by removing stud-
ies with small sample sizes (<30 participants) from the pooled
data or by removing those with a high risk of selection bias.
Participant characteristics
Table 1 is a summary of characteristics of the three included
studies. Across all studies, there was a total of 231 participants,
with 117 receiving an exercise intervention and 114 controls.
Total participants ranged from 124 [32] to 17 [33]. The 2003
Rotterdam criteria was used to reach a PCOS diagnosis in all
three studies [31–33]. The mean age of participants was
26 years, ranging from 22 [31] to 28 years [33].
Intervention characteristics
The exercise intervention duration in two studies was three
months [31, 32], and one was 16 weeks [33]. All of the studies
had an exercise frequency of three times per week [31–33].
Table 2 Mean difference, 95%
CI, P and I2 value for each
outcome analysed
Outcome Studies N MD Lower Upper P I2 (%)
HDL-C (mg/dL) 3 231 −2.97 −6.62 0.68 0.11 0
LDL-C (mg/dL) 3 231 −4.10 −13.32 5.22 0.39 42
TC (mg/dL) 3 231 −4.78 −9.24 −0.32 0.04 14
TG (mg/dL) 2 214 1.55 −4.66 7.76 0.63 0
Fasting Glucose (mg/dL) 2 214 −1.75 −3.46 −0.04 0.04 0
WC (cm) 2 107 −1.97 −3.35 −0.59 0.005 0
WHR 2 214 −0.05 −0.08 −0.02 0.0003 0
TT (nmol/L) 3 231 −0.20 −0.38 −0.02 0.03 47
SHBG (nmol/L) 2 141 4.05 1.79 6.31 0.0004 0
CRP (mg/L) 2 214 −0.34 −0.54 −0.15 0.0006 0
SBP (rest) (mmHg) 2 214 −4.40 −7.13 −1.66 0.002 0
DBP (rest) (mmHg) 2 214 −0.80 −1.96 0.37 0.18 0
N number of participants;MDMean difference; LDL-C low-density lipoprotein cholesterol; HDL-C high-density
lipoprotein cholesterol; TC total cholesterol; TG triglycerides;WC waist circumference;WHR waist-to-hip ratio;
TT total testosterone; SHBG sex hormone-binding globulin; HOMA-IR homeostatic assessment of insulin resis-
tance; SBP systolic blood pressure; DBP diastolic blood pressure; CRP C-reactive protein
Fig. 4 Forest plot of comparison: 1 – all interventions, outcome: 1.1 – HDL-C (mg/dL)
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One study began with three sessions per week for 11 weeks
and then progressed to five sessions per week for five weeks
[33]. Exercise intensity was determined by a percentage of
VO2max [31, 32] or heart rate reserve (HRR) [33]. All were
aerobic exercise interventions. Session length was 30 min in
all three studies [31–33] increasing to 45min after 11 weeks in
one [33]. Two studies were performed on a bicycle er-
gometer [31, 32], and one was performed on a station-
ary cycle, treadmill or elliptical machine according to partici-
pant preference [33].
All three studies reported that all participants completed the
study protocol [31–33]. All studies reported a mean adherence
of ≥80%. All studies included women of reproductive age
with a confirmed PCOS diagnosis. All studies specifically
mentioned exclusion of participants who were taking OCP,
metformin, or other hormonal, anti-androgen or carbohydrate
metabolism modification drugs. All studies also specifically
mentioned the exclusion of other conditions that could pro-
mote hyperandrogenism, such as Cushing’s Syndrome and
congenital adrenal hyperplasia. All studies excluded
those with thyroid dysfunction, diabetes, cardiovascular
disease or other renal or hepatic diseases. Only one
study confirmed exclusion of smokers and the exclusion
or participants who undertook regular exercise [33].
Two studies did not specify a formal sample size calculation
[31, 32] and another based this on an outcome of flow-
mediated dilation [33].
Risk of bias in included studies
The authors’ judgements about each risk of bias category are
presented as percentages across all included studies in Fig. 2.
A summary of the authors’ judgements of each risk of bias
item for each included study are presented in Fig. 3. Further
information outlining how each judgement was reached for
each category in each included study is available in
Online Resource 2.
Two studies (66.6%) were judged to have a high risk of
selection bias because participants were allocated to groups
based on their own choice [32, 33] and one (33.3%) was
judged to have an unclear risk of selection bias because the
authors did not report a method for randomisation or alloca-
tion concealment [31].
Performance bias was excluded from the assessment as all
the studies included supervised exercise sessions so it is im-
possible to blind participants to this type of intervention while
promoting exercise behaviour. Two studies (66.6%) were
judged to have a low risk of detection bias because the
blinding of outcome assessment was ensured, or the outcome
measurement was not likely to be influenced by lack of
blinding [31, 32]. The remaining study was judged to have
an unclear risk of detection bias because the authors did not
address this outcome. All studies were judged to have a low
risk of attrition bias either due to zero reported attrition rate,
and all were judged to have an unclear risk of reporting bias
because prospective protocols could not be located [31–33].
Additionally, we assessed whether of adherence (reported as
<80%) may have presented a high risk of ‘other sources of
bias’, and all were judged to be at a low risk [31–33].
Reporting of outcomes
All three studies reported on outcomes relating to lipid profile
(such as HDL-C, LDL-C, TC and TG) but no studies reported
oxidised LDL. All studies included either WC or WHR. Two
studies reported fasting blood glucose and HOMA-IR mea-
sures [31, 33], and one reported just fasting blood glucose
[32]. On androgen profile, all three studies reported total tes-
tosterone [31–33] and two reported sex hormone binding
globulin (SHBG) in addition [32, 33]. Two studies reported
systolic blood pressure (SBP) and diastolic blood pressure
(DBP) [31, 32]. Only two studies reported inflammation
markers and both of those reported C-reactive protein (CRP)
[31, 32].
Fig. 6 Forest plot of comparison: 1 – all interventions, outcome: 1.3 – TC (mg/dL)
Fig. 5 Forest plot of comparison: 1 – all interventions, outcome: 1.1 – LDL-C (mg/dL)
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Effects of exercise versus control
Following our study inclusion criteria, only three studies
could be included in the meta-analysis. As such, subgroup
analyses of exercise intensity, type and frequency were not
performed. Subgroup analysis for intervention duration may
have been possible, but given there would be two studies in
one category and one in the other, it was deemed to be unin-
formative and potentially misleading [34]. Effect estimates,
95% CI and I2 values are listed in Table 2 for each outcome.
Additionally, free testosteronemeasures were not available.
Total testosterone measures indicated that the mean values for
participants (231) in the studies eligible for meta-analysis
were hyper-androgenemic, based on total testosterone (TT)
concentrations of >2.0 nmol/L [35–37], therefore subgroup-
analysis of androgen profile could not be conducted.
Primary outcomes
Blood lipids All three studies (231 participants) in the meta-
analysis assessed changes in LDL-C, HDL-C, TC and TG
(231 participants). We observed no effect of exercise versus
control on LDL-C, HDL-C or TG.We found a statistical effect
of exercise on TC versus control (−4.70 mg/dl, 95% CI -9.24,
−0.32, I2 = 14%). When the study with a small sample size
was removed [33], the effect was no longer statistically
significant.
Of the three studies in the analysis, one reported a signifi-
cant decrease in LDL-C (−0.7 mmol/L, 95% CI -1.1 to −0.3,
P = 0.001) and TC (−0.20 mmol/L, 95% CI -0.28 to −0.04,
P = 0.01) when compared to the control group [33].
Fasting blood glucoseData from the three studies (231 partic-
ipants) pooled in the meta-analysis showed a significant
favourable effect of exercise on fasting glucose concentrations
versus controls (−1.75 mg/dL, 95% CI -3.45, −0.5, I2 = 0%).
When the study with a small sample size was removed [33],
the effect remained significant (−1.75 mg/dL, 95% CI -3.46,
−0.4, 214 participants, I2 = 0%).
Measures of abdominal obesity Two studies (107 participants)
were pooled in the meta-analysis to assess changes to WC and
WHR. A statistical favourable effect of exercise on WC
(−1.97 cm, 95% CI -3.35, −0.59, I2 = 0%) and a small but statis-
tical favourable effect of exercise onWHR (−0.05, 95%CI -0.09,
−0.01, I2 = 0%) compared to the control group was observed.
One study reported a significant decrease inWC (P < 0.01)
and WHR (P < 0.05) in the exercise group when compared to
the control group [31]. One other reported significant de-
creases in WHR (P < 0.05) in the exercise group compared
to control [32].
Blood pressure Two studies (214 participants) were pooled in
the meta-analysis to assess changes in SBP and DBP at
rest. The results indicated a statistical favourable effect
of exercise on SBP in comparison to controls (−4.40 mmHg,
95% CI -7.13, −1.66, I2 = 0%) but no effect was ob-
served for DBP.
Of the two studies reporting SBP and DBP, one did not note
any statistical effect of exercise on SBP or DBP in comparison
to controls [32]. The other study [31] reported a significant (P <
0.01) decrease in SBP after the exercise intervention, but this
was not significant in comparison to the control group.
C-reactive protein Two studies (114 participants) included in
the meta-analysis recorded changes in CRP. The authors ob-
served a small but statistical favourable effect of exercise on
CRP compared to controls (−0.34 mg/l, 95% CI -0.54, −0.14,
I2 = 0%). Both studies had a sample size >30.
Of the two studies one reported significant improvement
after exercise only [31] and the other found significant im-
provement after exercise and between-groups [32]. Both stud-
ies were ≥ 12 weeks in duration, with sessions of 30 min on a
bicycle ergometer.
Fig. 8 Forest plot of comparison: 1 – all interventions, outcome: 1.5 – Fasting blood glucose (mg/dL)
Fig. 7 Forest plot of comparison: 1 – all interventions, outcome: 1.4 – TG (mg/dL)
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Secondary outcomes
Total Testosterone and sex hormone binding globulin Three
studies (231 participants) were pooled to assess changes
in TT. The authors found a significant favourable effect
of exercise on TT compared to controls, although mod-
erate heterogeneity was noted (−0.20 nmol/l, 95% CI -
0.38, −0.02, I2 = 47%). Removal of the study with a
small sample size [33] mitigated I2 to 35% and in-
creased the statistical effect estimate (−0.24 nmol/l,
95% CI -0.43, −0.05, 114 participants). The same result
was also observed when removing the study with the highest
risk of bias [33].
Only two of the studies reporting TT also reported changes
to SHBG (114 participants). The meta-analysis indicated a
favourable effect of exercise on SHBG concentrations (4.10,
95% CI 1.79, 6.31, I2 = 0%). However, of note, both studies
had a high risk of bias in two domains.
Homeostatic model assessment of insulin resistanceOnly one
study eligible for meta-analysis reported HOMA-IR and as
such pooled analysis could not be conducted. No studies re-
ported any significant improvement in HOMA-IR after
exercise.
Figures 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 show the
comparisons for each outcome and subsequent forest plot.
Quality of the evidence
Using GRADE, Table 3 provides an evidence profile to
reflect the extent of confidence that each estimate of
effect from the pooled data-analysis is correct.
Evidence has been downgraded for all outcomes due
to the presence of serious study design limitations, including
small sample size (≤30 participants), unclear or inappropriate
randomisation or allocation procedures and non-randomised
controlled trials. Subsequently, all evidence could only begin
at a maximum of moderate quality.
Moderate heterogeneity was observed for only one
outcome. Also, there was no important inconsistency
of mean post-intervention values in most of the analy-
ses. No outcomes were downgraded for indirectness,
because all studies directly compared an exercise inter-
vention versus usual care or control, with explicit ex-
clusions of confounding medications. Where CI were
wide or indicated possible benefit in both directions,
evidence was downgraded due to imprecision and un-
certainty of results. Publication bias of all outcomes was
considered unlikely, since the authors conducted a thor-
ough and comprehensive search of relevant databases,
and no studies eligible for analysis declared any conflict
of interest or funding sources that may have influenced
publication.
Discussion
This systematic review and meta-analysis identified three
studies, including 231 participants with PCOS, that isolated
and examined the effect of structured, supervised exercise on
cardiometabolic outcomes in PCOS. Various recently
published reviews have examined the effects of exercise
and/or lifestyle modification on facets of PCOS [17,
38–40]. To the authors’ knowledge, this is the only
recent review that has aimed to isolate the effects of exercise
alone in comparison with control/standard care, without the
inclusion of dietary, pharmacological or behavioural modifi-
cation programmes.
Summary of main findings
Analysis of pooled data indicated, in the comparison of exer-
cise and control, statistical favourable effects of exercise on
TC, fasting glucose, WC, WHR, SBP, CRP, TT and SHBG
using post-intervention scores. This supports the role of exer-
cise as a treatment in the improvement of several
Fig. 10 Forest plot of comparison: 1 – all interventions, outcome: 1.7 – Waist-to-hip ratio
Fig. 9 Forest plot of comparison: 1 – all interventions, outcome: 1.6 – Waist circumference (cm)
J Diabetes Metab Disord
cardiovascular risk factors in PCOS, including abdomi-
nal adiposity, insulin sensitivity, endothelial dysfunction
and androgen profile.
Primary outcomes
The authors found a statistically-significant effect of exercise
was observed on TC versus control (−4.70 mg/dl, 95% CI -
9.24, −0.32, I2 = 14%), P = 0.04, but meta-analysis revealed
no other significant changes to lipid profile in PCOS women.
Other reviews have produced inconsistent results; a compre-
hensive, qualitative review [17] mostly found no significant
effects of exercise only (without a dietary component) on lipid
profile in PCOS, and those studies reporting significant im-
provements in TC involved a combined dietary and exercise
component. Conversely, a recent review [38] noted a statisti-
cal effect of exercise on TC concentrations in PCOS in a
pooled meta-analysis of just two studies (−0.09 mmol/L,
95% CI -0.10, −0.07), though it is not clear if this was based
on exercise versus control only. Subsequently, sensitivity anal-
ysis rendered the pooled effect estimate non-significant.
Additionally, since TC is the sum of LDL-C and
HDL-C, the clinical relevance of this measure may be
misleading, since LDL-C and HDL-C have contrasting
roles within the vascular system and a change to either
would affect the measure of TC [41]. TC:HDL appears
to be a better predictor of cardiovascular risk than TC or
LDL-C [42, 43].
Despite these results, exercise has been shown to have a
positive effect on HDL-C and TG in healthy populations and
those presenting with metabolic syndrome [44–46] with the
latter sharing some cardiovascular risk factors with PCOS.
This discrepancy may be due to the intervention characteris-
tics shared by the three included studies (3/week,
30 min-session). It has been reported that that changes
to HDL-C and TG are more likely with an energy ex-
penditure of 1200 kcal/week [45]; these interventions
may be unlikely to produce this output at lower inten-
sities. Additionally, a 2004 review [44] indicates that
interventions should be longer in duration (>20 weeks) to
induce positive changes to HDL-C and TG in people with
metabolic syndrome.
Pooled analysis of post-intervention values indicated a sig-
nificant effect estimate of exercise versus control on fasting
glucose concentrations (−1.75 mg/dl, 95% CI -3.45, −0.5,
I2 = 0%), P = 0.04. This effect remained significant after sen-
sitivity analysis. This finding is in line with a recent review
that indicated a statistically significant effect estimate of life-
style modification versus minimal intervention on fasting
blood glucose in PCOS (−2.3 mg/dL, 95% CI, −4.5 to −0.1,
I2 = 72%) P = 0.04 [39]. However, statistical heterogeneity
was noted, and exercise and dietary/behavioural modification
were combined under ‘lifestyle intervention’. Two other re-
views [38, 40] found no significant effects of lifestyle or ex-
ercise interventions on fasting blood glucose in PCOS.
Despite this, various studies have demonstrated that aerobic
exercise training enhances glucose disposal rate in women
with PCOS [12, 47]. The mean fasting blood glucose range
for the three studies in the pooled analysis was 84.6–95.6 mg/
dL, which are all considered to be in the normal range of
<100 mg/dL [48]. This is not unusual, because women with
PCOS can maintain normal fasting glucose at the expense of
increased insulin secretion [36]. Nevertheless, it is difficult to
assess the clinical relevance of this outcome without compar-
ative data on insulin sensitivity.
We noted a statistically-favourable effect of exercise versus
control onWC (−1.97 cm, 95%CI -3.35, −0.59, I2 = 0%), P =
0.005, and WHR (−0.05, 95% CI -0.09, −0.01, I2 = 0), P =
0.003, in two studies. This is in agreement with two other
reviews [38, 40], although one combined exercise and dietary
modification under lifestyle intervention [40]. WC and WHR
have been shown to be, in some cases, a better indicator of
health risk than BMI [49] because they measure abdominal
obesity, a condition strongly associated with cardiovascular
Fig. 11 Forest plot of comparison: 1 – all interventions, outcome: 1.8 – Total testosterone (nmol/L)
Fig. 12 Forest plot of comparison: 1 – all interventions, outcome: 1.9 – Sex hormone-binding globulin (nmol/L)
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risk factors [50]. A decrease in WC and WHR has also been
associated with improvements in glucose metabolism [51].
The authors observed that exercise had a statistically-
significant effect on SBP in comparison to control
(4.40 mmHg, 95% CI -7.13, −1.66, I2 = 0%), P = 0.0003.
This has been observed after lifestyle intervention in PCOS
in another review (−5.01 mmHg, 95% CI -6.63, −3.39,
P < 0.05, I2 = 0%) [38]. A meta-analysis of RCTs [52] has
indicated that aerobic exercise training produces a small but
statistical improvement in blood pressure, even in the absence
of weight loss, in normotensive adults. Blood pressure values
among this population have been inversely associated
with insulin sensitivity [44]. The mean data from the
meta-analysis indicates that participants were normoten-
sive (≤120 mmHg). We observed improvements of WC
and WHR, shown to be associated with insulin sensitiv-
ity in PCOS [53]. As such, improvement in insulin reg-
ulation is a plausible explanation for several of the ob-
served effect estimates.
We observed a favourable statistical effect of exercise on
CRP versus control (−0.34 mg/l, 95% CI -0.54, −0.14, I2 =
0%) P < 0.001. This finding is in agreement with another re-
view that found favourable effects of lifestyle modification
versus usual care (−0.47 mmol/L, 95% CI -0.80, −0.15, P =
0.004, I2 = 0%). Indeed, PCOS has been linked to an inflam-
matory state characterised by increased levels of CRP
[19, 54]. However, the clinical relevance of this finding
may be tenuous; the mean CRP range for the studies in
the pooled analysis was 1.54–1.92 mg/L, which are con-
sidered to be within the normal range [55] and as such this
may not indicate an inflammatory state in the participants.
Also, the effect may not be reproduced in populations with a
higher than normal value.
Secondary outcomes
Pooled data analysis indicated a statistical favourable effect of
exercise versus control on TT(−0.20 nmol/L, 95% CI -0.38,
−0.02, I2 = 47%) P = 0.03, and SHBG (4.05, 95% CI 1.79,
6.31, I2 = 0%) P < 0.001. Both outcomes were derived from
at least one study with a high risk of bias for randomisation
and allocation procedures. Nevertheless, a previous review
has noted a statistical lowering of fasting insulin levels in the
exercise group compared to the control group in PCOS (−0.95
μU/mL, 95% CI -1.48, −0.43, P < 0.05, I2 = 0%) [38].
Additionally, a qualitative systematic review found evidence
for improved insulin sensitivity following exercise in PCOS
[17]. An improvement in insulin sensitivity following exercise
could therefore be an explanation for both reduced TT and
increased SHBG; hyperinsulinemia causes an increase in free
androgen plasmatic levels both through the stimulation of
ovarian androgen synthesis, and by suppressing hepatic pro-
duction of SHBG [56]. We were not able to perform a meta-
analysis on free testosterone; caution is advised when measur-
ing TT alone, because women with PCOS can have TT in the
normal range but have high concentrations of free and bio-
available testosterone due to lower concentrations of SHBG
[36]. However, the data indicate that the participants in the
meta-analysis had low enough SHBG concentrations
(<30 nmol/L), even post-intervention, to indicate
hyperandrogenism [36]. This provides further plausibility to
the explanation that exercise may have mitigated insulin hy-
persecretion, thereby increasing hepatic production of SHBG
and reducing ovarian androgen synthesis to the effect of re-
duced TT.
Overall completeness and applicability of evidence
One study in the analysis was an RCTand two were non-RCT.
This limits the overall applicability of the evidence, par-
ticularly where participants were allocated to groups
based on preference. Although the studies specified no
statistical differences in baseline characteristics, it is
possible that the adherence and attrition rates are not
truly reflective of those that would be observed in gold-
standard RCTs.
Fig. 13 Forest plot of comparison: 1 – all interventions, outcome: 1.10 – C-reactive protein (mg/L)
Fig. 14 Forest plot of comparison: 1 – all interventions, outcome: 1.11 – Systolic blood pressure (rest) (mmHg)
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Only one study specified formal sample size calculations,
and this study had a small sample size (17 participants). In
samples of this size, variance in scores is likely to affect sta-
tistical significance and applicability to the general PCOS
population is limited.
Sub-group analysis based on androgen profile was not pos-
sible, because the studies included in the meta-analysis indi-
cated that the mean TT concentration for all participants were
high enough to constitute hyperandrogenemia. Typical cut-off
values of TT for hyperandrogenemia are generally
>2.1 nmol/L [36, 37] and post-intervention values for all par-
ticipants in the meta-analysis (n = 231) ranged from 2.1–
2.5 nmol/L. The results of the meta-analysis may therefore
have limited applicability to normo-androgenic phenotypes
and differences in treatment responsiveness between pheno-
types have not been highlighted.
An important characteristic of the review was to only in-
clude trials where OCP was clearly excluded. The authors
wanted to avoid the contamination of the data by the hormonal
and metabolic changes associated with the OCP, particularly
those with low or anti-androgenic properties, such as hepatic
synthesis of SHBG that reduces free testosterone concentra-
tions [57]. Additionally, in overweight or obese women with
PCOS, research suggests that certain types of OCP containing
desogestral or cyproterone acetate can aggravate insulin resis-
tance and decrease glucose tolerance [58–60]. Because of the
considerable variability in the presentation of clinical and met-
abolic symptoms of PCOS, including varying levels of glu-
cose tolerance, hyperandrogenism and insulin sensitivity, as
well as the variation in the types and metabolic effects of
OCPs used to manage PCOS symptoms, we excluded those
participants taking OCP to reduce the effects of inter-person
variability in the meta-analysis.
PCOS is the most common cause of infertility [61]. It is
estimated that 40% of women with PCOS are affected by
infertility or difficulty conceiving [62]. As a result, approxi-
mately up to 95% of anovulatory women seeking or
receiving fertility treatment have PCOS [45]. Therefore, al-
though OCP may be a front-line management tool in PCOS
in women not aiming to conceive [58], there exists a substan-
tial proportion of women with PCOS that are not taking OCP,
many of whom are encouraged to improve their health to
increase chances of conception, indicating that the findings
of this review have applicability to this subset of the
population.
Potential biases in the review process and limitations
We restricted our eligibility criteria to articles published in the
English language. Consequently, it is possible that additional
information from trials that would have otherwise met the
inclusion criteria may have been excluded. Also, trials were
only eligible for inclusion if the full-text could be obtained;
subsequently at least one eligible trial could not be included
because the abstract was for a conference and the full-text had
not been published. These factors may contribute to publica-
tion bias. Due to a lack of trials in the meta-analysis, funnel
plots could not be utilised for the analysis of publication bias.
Some difficulty in study selection occurred due to a lack of
trials that explicitly excluded the use of OCP and other hor-
monal or metabolism-altering drugs. The authors could only
select studies if this was specifically excluded, and as such
some studies may have been excluded for not providing such
a statement. Similarly, at least one gold-standard RCT was
excluded due to the use of non-normally distributed data and
non-parametric tests. These data could have influenced find-
ings if they could be synthesised for meta-analysis and thus
had to be excluded.
Many of the outcomes were based on studies with serious
limitations, including a high risk of selection bias, and small
magnitude effect estimates. This limits the quality of the evi-
dence, despite the directness and consistency of the evidence
for most outcomes. As noted, the generalisability may also be
limited by the high occurrence and selection bias, and partic-
ularly by study designs which allowed participant allocation
based on preference rather than true randomisation.
Future research recommendations
Most studies featured moderate-intensity aerobic interven-
tions, with less emphasis on resistance training in the litera-
ture, therefore different types of exercise intervention could
not be compared. Current physical activity guidelines recom-
mend that adults undertake activity to improve muscle
strength on at least two days a week [63]. As such, a greater
emphasis should be placed on the inclusion of resistance ex-
ercises in exercise interventions to identify additional benefits
to cardiometabolic health in PCOS. Future consideration
could also be given to tools for self-reporting physical activity,
such as the Global Physical Activity Questionnaire, as well as
interventional studies.
Fig. 15 Forest plot of comparison: 1 – all interventions, outcome: 1.12 – Diastolic blood pressure (rest) (mmHg)
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Conclusions
The results of the pooled data analysis indicated that moderate
aerobic exercise interventions ≥3 months in duration, with a
frequency of 3/week for at least 30-min-long sessions, may
have favourable effects on various cardiometabolic risk fac-
tors including TC, fasting blood glucose,WC,WHR, SBP and
CRP in women with PCOS. Additionally, we observed that if
participants have TT and SHBG concentrations outside of
normal ranges, this type of intervention could improve andro-
gen profile in comparison to usual care.
As indicated by our analysis of the quality of the evidence,
various outcomes were judged to be of a moderate quality, with
statistically significant, precise effect estimates. Nonetheless,
results should be interpreted with caution due to the presence
of serious methodological limitations including a lack of gold-
standard RCTs and a high risk of selection bias.
We conducted a thorough search of nine databases from
inception to present but were only able to find three eligible
studies that isolated the effects of exercise alone versus usual
care that explicitly excluded the use of OCP and other hormonal
or metabolism-altering drugs. Only one of these was a gold-
standard RCT, albeit judged to have an unclear risk of selection
bias due to unclear randomisation or allocation procedures.
This review highlights the limitations of the available literature.
More gold-standard RCTs that can make direct comparisons
between treatment options for PCOS, including exercise, phar-
macological, behavioural and dietary interventions could pro-
vide greater precision for future recommendations of treatment
options, including the efficacy of exercise in comparison to
other treatments. However, the authors acknowledge that this
may have limited applicability to the general population; often,
patients with PCOS may undertake combined interventions to
get the best results, and studies designed in this manner may
provide greater applicability in that regard.
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